First patient enrolled in head-to-head study of MS treatment

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

First patient enrolled in head-to-head study of MS treatment

Postby MSUK » Thu Mar 25, 2010 12:46 am

Study to evaluate possible benefits of switching to Tysabri from Copaxone or Rebif commences. - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2212
Joined: Wed Oct 14, 2009 2:00 pm

Advertisement

Re: First patient enrolled in head-to-head study of MS treat

Postby HarryZ » Thu Mar 25, 2010 5:44 am

squiffy2 wrote:Study to evaluate possible benefits of switching to Tysabri from Copaxone or Rebif commences. - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768


Not surprising that Biogen is conducting this study. Their market share of MS patients using Tysabri is far short of what they expected at this point in time. And with the risk of PML climbing each month, they have to do something to prop up sales.

Considering that the efficacy of the CRAB drugs is not very good, it won't take much in this trial to show that Tysabri gives better results. And guess who is going to pay for this trial in the long run?

Harry
User avatar
HarryZ
Family Elder
 
Posts: 2557
Joined: Tue May 25, 2004 2:00 pm
Location: London, ON, Canada


Return to Tysabri (Antegren or Natalizumab)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service